Floatz logo

INDOMETACINUM

Catheter-related Bladder Discomfort (CRBD)

Zhejiang UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Catheter-related Bladder Discomfort (CRBD) cohort.

Asset / SponsorPhaseRating
Tamsulosin
Centre Hospitalier Universitaire de Nīmes
Phase 3BB
Cranberry
Rennes University Hospital
Phase 3B
Oxybutynin Transdermal Patch
University of California, Davis
Phase 3B
Oxybutynin
University of California, Davis
Phase 3B
Alfuzosin
Nova Scotia Health Authority
Phase 2/3CCC

View all 10 →

Same molecule, other indications

INDOMETACINUM is also rated in:

migraine disorderDormant
BB
Indicative ·
66 / 100
View asset →
prostate cancerDormant
B
Indicative ·
63 / 100
View asset →
cutaneous melanomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →